WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, January 02, 2008

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT; PLUR=YES; OP=ADJ		
☐	L24	L23 and (@AD<20020823 or @PRAD<20020823 or @RLAD<20020823)	49
☐	L23	L21 and (hyperglycem$ or diabet$)	80
☐	L22	L21 and (sodium-dependent glucose cotransporter)	3
☐	L21	L19 and (pyrazole)	121
☐	L20	L19 and ($pyrazole.ab. or $pyrazole.clm.)	42
☐	L19	514/27.icls. or 514/27.ccls. or 536/17.4.icls. or 536/17.4.ccls.	1767
☐	L18	L17 and pyrazole	26
☐	L17	Kissei.as.	119

END OF SEARCH HISTORY

```
     FILE 'REGISTRY' ENTERED AT 14:10:56 ON 02 JAN 2008
L1                STRUCTURE UPLOADED
L2             10 S L1
L3            261 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:12:04 ON 02 JAN 2008
L4              2 S L3
```

```
=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:10:56 ON 02 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     1 JAN 2008  HIGHEST RN 959833-82-0
DICTIONARY FILE UPDATES:    1 JAN 2008  HIGHEST RN 959833-82-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10525197generic.str
```





chain nodes :
7 13 20 21 22 23 24 25 28 31 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 14 15 16 17 18 19
chain bonds :
2-7 5-33 7-8 9-31 12-13 13-14 14-36 15-20 15-37 16-21 16-38 17-22 17-39
18-23 18-40 23-24 33-34 34-35
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12 14-15 14-19 15-16
16-17 17-18 18-19
exact/norm bonds :
5-33 8-9 8-12 9-10 9-31 10-11 11-12 12-13 13-14 14-15 14-19 15-16 15-20
16-17 16-21 17-18 17-22 18-19 33-34 34-35
exact bonds :
2-7 7-8 14-36 15-37 16-38 17-39 18-23 18-40 23-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

G2:O,S,C

Connectivity :

25:1 X maximum RC ring/chain 28:0 E exact RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 28:Atom 31:CLASS 33:CLASS 34:CLASS
35:CLASS 36:CLASS
37:CLASS 38:CLASS 39:CLASS 40:CLASS
Generic attributes :
25:
Number of Carbon Atoms : less than 7
28:
Saturation   : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System   : Monocyclic

L1   STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 14:11:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   28 TO ITERATE

100.0% PROCESSED   28 ITERATIONS   10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 243 TO   877
PROJECTED ANSWERS: 11 TO   389

L2   10 SEA SSS SAM L1

=> d l2 scan

L2   10 ANSWERS   REGISTRY COPYRIGHT 2008 ACS on STN
IN   Benzenebutanamide, N-(2-amino-2-oxoethyl)-4-[[3-(β-D-
     glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-
MF   C25 H36 N4 O8

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Piperazinecarboxylic acid, 4-[3-[[2-[4-[[3-(β-D-galactopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]ethyl]amino]-2,2-dimethyl-1,3-dioxopropyl]-, phenylmethyl ester
MF C39 H53 N5 O11

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN β-Alanine, N2-[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]propyl]-L-α-

asparaginyl-N-(phenylmethyl)-, phenylmethyl ester (9CI)
MF C44 H57 N5 O11

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss full
FULL SEARCH INITIATED 14:12:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 657 TO ITERATE

100.0% PROCESSED 657 ITERATIONS 261 ANSWERS
SEARCH TIME: 00.00.01

L3 261 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.82	179.03

FILE 'CAPLUS' ENTERED AT 14:12:04 ON 02 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Jan 2008 VOL 148 ISS 1

FILE LAST UPDATED: 1 Jan 2008 (20080101/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 2 L3

=> d l4 1-2 ti abs bib hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of 4-benzylpyrazolyl glucopyranosides and galactopyranoside derivatives as sodium-glucose cotransporter (SGLT1) inhibitors, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
GI



I

AB Pyrazole derivs. represented by the general formula (I) [R1 = H, C1-6 alkyl, C2-6 alkenyl, hydroxy-C2-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, each (un)substituted aryl or aryl-C1-6 alkyl; one of Q and T = Q1 or Q2 and the other = C1-6 alkyl, halo-C1-5 alkyl, C1-6 alkoxy-C1-6 alkyl, C3-7 cycloalkyl; R2 = H,halo, OH, C1-6 alkyl, C1-6 alkoxy,C1-6 alkylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C3-7 cycloalkyl-C2-6 alkoxy, etc.; X = a single bond, O, S; Y = optionally hydroxy-substituted C1-6 alkylene or C2-6 alkenylene; Z = RB, CORC, SO2RC, CO(RD)RE, SO2NHRF, C(:NRG)N(RH)RI; wherein RC = each (un)substituted aryl, heteroaryl, or C1-6 alkyl; R4, RB, RD, RE, RF = H, each (un)substituted aryl, heteroaryl, or C1-6 alkyl; NR4RB or NRDRE together forms (un)substituted C2-6 cyclic amino; RG, RH, RI = H, (un)substituted C1-6 alkyl, etc.; R3, R5, R6 = H, halo, C1-6 alkyl, C1-6 alkoxy] or pharmacol. acceptable salts thereof are prepared These compds. have excellent human SGLT1 inhibitory activity and are useful as preventives or therapeutic agents for diseases attributable to hyperglycemia such as diabetes, impaired glucose tolerance, fasting blood sugar abnormality, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hypertriglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout and for diseases attributable to an increased blood galactose level such as galactosemia. For example, 3-(β-D-glucopyranosyloxy)-4-[[4-[3-[3-(2-hydroxy-1,1-dimethylethyl)ureido]propoxy]-2-methylphenyl]methyl]-5-isopropyl-1H-

pyrazole in vitro inhibited the uptake of [14C]methyl α-D-glucopyranoside in CHO-K1 cells expressing human SGLT1 with IC50 of 19 nM. For another example, 3-(β-D-glucopyranosyloxy)-4-[[4-(2-guanidinoethoxy)-2-methylphenyl]methyl]-5-isopropyl-1H-pyrazole at 1 mg/kg p.o. lowered the serum glucose concentration from 303±63 (control) to 165±17 mg/dL after 1 h in rats with streptozotocin-induced diabetes.

AN 2004:182896 CAPLUS <<LOGINID::20080102>>

DN 140:236000

TI Preparation of 4-benzylpyrazolyl glucopyranosides and galactopyranoside derivatives as sodium-glucose cotransporter (SGLT1) inhibitors, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof

IN Fushimi, Nobuhiko; Shimizu, Kazuo; Yonekubo, Shigeru; Teranishi, Hirotaka; Tomae, Masaki; Isaji, Masayuki

PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 270 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018491	A1	20040304	WO 2003-JP10551	20030821
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004137245	A	20040513	JP 2002-324076	20021107
	CA 2496329	A1	20040304	CA 2003-2496329	20030821
	AU 2003262263	A1	20040311	AU 2003-262263	20030821
	EP 1548024	A1	20050629	EP 2003-792760	20030821
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013694	A	20050705	BR 2003-13694	20030821
	CN 1688597	A	20051026	CN 2003-824499	20030821
	ZA 2005001549	A	20060726	ZA 2005-1549	20030821
	NZ 538423	A	20070223	NZ 2003-538423	20030821
	US 2005272669	A1	20051208	US 2005-525197	20050222
	MX 2005PA02129	A	20050603	MX 2005-PA2129	20050223
	NO 2005001411	A	20050426	NO 2005-1411	20050317
	IN 2007DN07100	A	20071012	IN 2007-DN7100	20070913
PRAI	JP 2002-244381	A	20020823		
	JP 2002-324076	A	20021107		
	WO 2003-JP10551	W	20030821		
	IN 2005-DN666	A3	20050221		

OS MARPAT 140:236000

IT 666841-92-5P 666841-93-6P 666841-94-7P
666841-95-8P 666841-96-9P 666841-97-0P
666841-98-1P 666841-99-2P 666842-00-8P
666842-01-9P 666842-03-1P 666842-05-3P
666842-06-4P 666842-07-5P 666842-08-6P
666842-09-7P 666842-10-0P 666842-11-1P
666842-12-2P 666842-13-3P 666842-14-4P
666842-15-5P 666842-16-6P 666842-17-7P
666842-18-8P 666842-19-9P 666842-22-4P
666842-23-5P 666842-24-6P 666842-31-5P
666842-32-6P 666842-33-7P 666842-34-8P
666842-35-9P 666842-36-0P 666842-37-1P

666842-38-2P 666842-39-3P 666842-40-6P
666842-41-7P 666842-42-8P 666842-43-9P
666842-44-0P 666842-45-1P 666842-46-2P
666842-47-3P 666842-48-4P 666842-49-5P
666842-50-8P 666842-51-9P 666842-52-0P
666842-53-1P 666842-54-2P 666842-55-3P
666842-57-5P 666842-58-6P 666842-59-7P
666842-60-0P 666842-61-1P 666842-62-2P
666842-63-3P 666842-64-4P 666842-65-5P
666842-66-6P 666842-67-7P 666842-68-8P
666842-69-9P 666842-70-2P 666842-71-3P
666842-72-4P 666842-73-5P 666842-74-6P
666842-75-7P 666842-78-0P 666842-79-1P
666842-90-6P 666842-91-7P 666842-92-8P
666842-93-9P 666842-94-0P 666842-95-1P
666842-96-2P 666842-97-3P 666842-98-4P
666842-99-5P 666843-00-1P 666843-01-2P
666843-02-3P 666843-03-4P 666843-04-5P
666843-05-6P 666843-06-7P 666843-07-8P
666843-08-9P 666843-09-0P 666843-10-3P
666843-11-4P 666843-12-5P 666843-13-6P
666843-14-7P 666843-15-8P 666843-16-9P
666843-17-0P 666843-18-1P 666843-19-2P
666843-22-7P 666843-23-8P 666843-24-9P
666843-25-0P 666843-26-1P 666843-27-2P
666843-28-3P 666843-29-4P 666843-30-7P
666843-31-8P 666843-32-9P 666843-33-0P
666843-34-1P 666843-35-2P 666843-36-3P
666843-37-4P 666843-38-5P 666843-39-6P
666843-40-9P 666843-41-0P 666843-42-1P
666843-43-2P 666843-44-3P 666843-45-4P
666843-46-5P 666843-47-6P 666843-48-7P
666843-49-8P 666843-50-1P 666843-51-2P
666843-52-3P 666843-53-4P 666843-54-5P
666843-56-7P 666843-57-8P 666843-58-9P
666843-59-0P 666843-60-3P 666843-61-4P
666843-62-5P 666843-63-6P 666843-64-7P
666843-65-8P 666843-67-0P 666843-69-2P
666852-18-2P 666852-20-6P 666852-22-8P
666852-24-0P

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of pyrazolyl glucopyranoside and galactopyranoside derivatives inhibitors of human sodium-glucose cotransporter 1 (SGLT1), medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
GI



AB Pyrazoles derivs. represented by the general formula (I) [R1 = H, C1-5 alkyl, C2-5 alkenyl, hydroxy-C2-5 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl (un)substituted aryl or aryl-C1-6 alkyl; one of Q and T = Q1, Q2 and the other = C1-5 alkyl, halo-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C3-7 cycloalkyl; R2 = H,halo, OH, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C3-7 cycloalkyl-C2-6 alkoxy, etc.; X = a single bond, O, S; Y = a single bond, C1-6 alkylene, C2-6 alkenylene; Z = CO, SO2; R4, R5 = H, (un)substituted C1-6 alkyl; or NR4R5 together forms an (un)substituted C2-6 cyclic amino; R3, R6, R7 = H, halo, C1-6 alkyl, C1-6 alkoxy] or pharmacol. acceptable salts thereof or prodrug of either are prepared These compds. have excellent human SGLT1 inhibitory activity and are useful as preventives or therapeutic agents for (1) diseases attributable to hyperglycemia such as diabetes, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hypertriglycemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, or gout and (2) diseases attributable to high level of galactose, galactosemia. For example, 3-(β-D-glucopyranosyloxy)-4-[[4-[3-[2-hydroxy-1,1-bis(hydroxymethyl)ethylcarbamoyl]propyl]phenyl]methyl]-5-isopropyl-1H-pyrazole at 1 mg/kg p.o. lowered blood glucose in diabetic rats from 297±35 to 178±19 mg/dL in 1 h.

AN 2004:143172 CAPLUS <<LOGINID::20080102>>

DN 140:199632

TI Preparation of pyrazolyl glucopyranoside and galactopyranoside derivatives inhibitors of human sodium-glucose cotransporter 1 (SGLT1), medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof

IN Teranishi, Hirotaka; Fushimi, Nobuhiko; Yonekubo, Shigeru; Shimizu, Kazuo; Shibazaki, Toshihide; Isaji, Masayuki

PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014932	A1	20040219	WO 2003-JP10048	20030807

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2494179	A1	20040219	CA 2003-2494179	20030807
AU	2003254847	A1	20040225	AU 2003-254847	20030807
EP	1544208	A1	20050622	EP 2003-784564	20030807
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR	2003013290	A	20050705	BR 2003-13290	20030807
CN	1688596	A	20051026	CN 2003-823929	20030807
NZ	538117	A	20070126	NZ 2003-538117	20030807
US	2006166899	A1	20060727	US 2005-523820	20050204
MX	2005PA01549	A	20050505	MX 2005-PA1549	20050208
NO	2005001209	A	20050415	NO 2005-1209	20050308
PRAI JP	2002-232074	A	20020808		
JP	2002-321729	A	20021105		
WO	2003-JP10048	W	20030807		

OS MARPAT 140:199632

IT 661479-26-1P 661479-27-2P 661479-28-3P
661479-29-4P 661479-30-7P 661479-31-8P
661479-32-9P 661479-34-1P 661479-36-3P
661479-37-4P 661479-38-5P 661479-39-6P
661479-40-9P 661479-41-0P 661479-42-1P
661479-44-3P 661479-45-4P 661479-46-5P
661479-47-6P 661479-48-7P 661479-49-8P
661479-50-1P 661479-51-2P 661479-52-3P
661479-53-4P 661479-61-4P 661479-63-6P
661479-65-8P 661479-67-0P 661479-76-1P
661479-77-2P 661479-78-3P 661479-79-4P
661479-80-7P 661479-81-8P 661479-85-2P
661479-86-3P 661479-87-4P 661479-88-5P
661479-89-6P 661479-90-9P 661479-92-1P
661479-93-2P 661479-94-3P 661479-95-4P
661479-96-5P 661479-97-6P 661479-98-7P
661479-99-8P 661480-03-1P 661480-04-2P
661480-05-3P 661480-07-5P 661480-08-6P
661480-09-7P 661480-10-0P 661480-12-2P
661480-13-3P 661480-14-4P 661480-15-5P
661480-16-6P 661480-17-7P 661480-18-8P
661480-19-9P 661480-20-2P 661480-21-3P
661480-22-4P 661480-24-6P 661480-25-7P
661480-26-8P 661480-27-9P 661480-29-1P
661480-32-6P 661480-35-9P 661480-37-1P
661480-39-3P 661480-41-7P 661480-42-8P
661480-43-9P 661480-44-0P 661480-46-2P
661480-48-4P 661480-49-5P 661480-51-9P
661480-53-1P 661480-54-2P 661480-55-3P
661480-56-4P 661480-57-5P 661480-58-6P
661480-59-7P 661480-60-0P 661480-62-2P
661480-63-3P 661480-64-4P 661480-65-5P
661480-66-6P 661480-67-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolyl glucopyranoside and galactopyranoside derivs. inhibitors of human sodium-glucose cotransporter 1 (SGLT1) for preventives or therapeutics for diseases related to hyperglycemia or galactosemia)

RN 661479-26-1 CAPLUS

CN Benzenebutanamide, N-(2-amino-2-oxoethyl)-4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX

NAME)

FILE 'REGISTRY' ENTERED AT 14:10:56 ON 02 JAN 2008

L1 STRUCTURE UPLOADED

L2 10 S L1

L3 261 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:12:04 ON 02 JAN 2008

L4 2 S L3